Intravitreal Bevacizumab vs. Triamcinolone for Patients with Diabetic Macular Edema at the Time of Cataract Surgery (DIMECAT)


May 1, 2020

Clinical trial

Diabetic retinopathy progression 6 months post-cataract surgery with intravitreous bevacizumab vs triamcinolone: A secondary analysis of the DiMECAT trial.

Sasongko MB, Rogers S, Constantinou M, Sandhu SS, Wickremasinghe SS, Al-Qureshi S, Lim LL.

Clin Exp Ophthalmol. 2020 Aug;48(6):793-801.
Full text | Metrics.

Share This Article :

Updated on March 7th, 2022

Source Archive